

# **Product Information Sheet for NR-2531**

# Genomic DNA from *Brucella abortus*, Strain 870 (NCTC 10505)

Catalog No. NR-2531

For research use only. Not for human use.

### **Contributor:**

ATCC®

#### **Product Description:**

Genomic DNA was isolated from a preparation of *Brucella abortus* (*B. abortus*), strain 870 (NCTC 10505).

*B. abortus* is a non-motile, aerobic, gram-negative coccobacillus which displays a moderate degree of human virulence. Very little is known about the genetics of *Brucella* virulence, largely due to a lack of classical virulence factors. A type IV secretion system has been identified as essential for intracellular survival and multiplication of *Brucella*. <sup>1</sup>

B. abortus 870 was isolated from bovine fetus in 1959 by Dr. R. G. Dijkstra.

NR-2531 has been qualified for PCR applications by amplification of  $\sim$  1430 bp of the 16S ribosomal RNA gene.

#### **Material Provided:**

Each vial contains approximately 2  $\mu g$  bacterial genomic DNA, lyophilized from 0.05 mL containing TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH ~ 8.0). The vial should be centrifuged prior to opening.

## Packaging/Storage:

NR-2531 was packaged aseptically in screw-capped plastic cryovials. The product is provided frozen and should be stored at 4°C or colder immediately upon arrival. For optimal long-term storage, freezing the material at -20°C or colder is recommended. Freeze-thaw cycles should be minimized.

#### Citation:

Acknowledgment for publications should read "The following reagent was obtained through the NIH Biodefense and Emerging Infections Research Resources Repository, NIAID, NIH: Genomic DNA from *Brucella abortus*, Strain 870 (NCTC 10505), NR-2531."

#### Biosafety Level: 1

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 4th ed. Washington, DC: U.S. Government Printing Office, 1999. HHS Publication No. (CDC) 93-8395. This text is available online at <a href="https://www.cdc.gov/od/ohs/biosfty/bmbl4/bmbl4toc.htm">www.cdc.gov/od/ohs/biosfty/bmbl4/bmbl4toc.htm</a>.

#### Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government make any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

#### **Use Restrictions:**

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

#### References:

- Boschiroli, M. L., et al. "Type IV Secretion and Brucella Virulence." <u>Vet. Microbiol.</u> 90 (2002): 341–348. PubMed: 12414154.
- Halling, S. M., et al. "Completion of the Genome Sequence of Brucella abortus and Comparison to the Highly Similar Genomes of Brucella melitensis and Brucella suis." <u>J. Bacteriol.</u> 187 (2005): 2715–2726. PubMed: 15805518.
- Chain, P. S. et al. "Whole-Genome Analyses of Speciation Events in Pathogenic Brucellae." <u>Infect.</u> <u>Immun.</u> 73 (2005): 8353–8361. PubMed: 16299333.
- Ratushna, V. G., et al. "Molecular Targets for Rapid Identification of *Brucella* spp." <u>BMC Microbiol.</u> 6 (2006): 13. PubMed: 16504063.
- Ciocchini, A. E., et al. "Identification of Active Site Residues of the Inverting Glycosyltransferase Cgs Required for the Synthesis of Cyclic β-1,2-Glucan, A Brucella abortus Virulence Factor." Glycobiology 16 (2006): 679–691. PubMed: 16603625.

 $\mathsf{ATCC}^{\$}$  is a trademark of the American Type Culture Collection.

**Biodefense and Emerging Infections Research Resources Repository** P.O. Box 4137

Manassas, VA 20108-4137 USA www.beiresources.org

E-mail: contact@beiresources.org

Fax: 703-365-2898

800-359-7370